A detailed history of State Street Corp transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 3,349,408 shares of VERV stock, worth $21.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,349,408
Previous 5,097,408 34.29%
Holding current value
$21.5 Million
Previous $67.7 Million 75.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $8.32 Million - $22.4 Million
-1,748,000 Reduced 34.29%
3,349,408 $16.3 Million
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $13.3 Million - $22.1 Million
1,230,644 Added 31.83%
5,097,408 $67.7 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $5.21 Million - $11 Million
589,584 Added 17.99%
3,866,764 $53.9 Million
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $2.45 Million - $4.46 Million
214,148 Added 6.99%
3,277,180 $43.5 Million
Q2 2023

Aug 14, 2023

SELL
$13.34 - $19.9 $3.83 Million - $5.71 Million
-286,745 Reduced 8.56%
3,063,032 $57.4 Million
Q1 2023

May 15, 2023

SELL
$14.3 - $24.01 $16 Million - $26.9 Million
-1,121,272 Reduced 25.08%
3,349,777 $48.3 Million
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $29.8 Million - $68 Million
1,671,215 Added 59.69%
4,471,049 $86.5 Million
Q3 2022

Nov 15, 2022

BUY
$15.63 - $41.49 $34.3 Million - $91.1 Million
2,194,551 Added 362.57%
2,799,834 $96.2 Million
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $22.9 Million - $47.7 Million
-2,057,823 Reduced 77.27%
605,283 $9.25 Million
Q1 2022

May 16, 2022

BUY
$20.92 - $39.36 $18.8 Million - $35.4 Million
899,742 Added 51.02%
2,663,106 $60.8 Million
Q4 2021

Feb 14, 2022

BUY
$31.94 - $54.82 $48.7 Million - $83.6 Million
1,524,355 Added 637.78%
1,763,364 $65 Million
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $11 Million - $17.7 Million
239,009 New
239,009 $11.2 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $384M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.